Project Grant CE153662
Award Date
9/30/24
Completion Date
9/29/27
Dollars Obligated
$826K
Funding Federal Agency
Healthcare Systems Bureau
Awarding Federal Agency
Office of Federal Assistance Management
Federal Grant Program
93.493
Assistance Type
Project Grant
Place of Performance
Girdwood, Anchorage, AK, USA
Similar Awards
The U.S. Department of Health and Human Services, through the Congressional Directives program (CFDA 93.493), awarded a $6,000,000 project grant to the Team Gleason Foundation in New Orleans, Louisiana. The grant, which runs from August 1, 2024 to July 31, 2025, is intended to "PROVIDE INNOVATIVE TECHNOLOGY, EQUIPMENT AND OTHER SOLUTION TO THOSE LIVING WITH ALS, AND TO THOSE WHO CARE FOR THEM, TO DELIVER GREATER INDEPENDENCE AND A HIGHER QUALITY OF LIFE." The Congressional Directives...
The Department of Defense's Defense Health Agency awarded a $921,600 Project Grant to The General Hospital Corporation (Massachusetts General Hospital) to research the "Therapeutic Effects of Sulfide Catabolism and Novel Trisulfide Compounds for Amyotrophic Lateral Sclerosis." The grant, under the Military Medical Research and Development program (CFDA 12.420), supports foundational biomedical research aimed at developing novel treatments for amyotrophic lateral sclerosis (ALS)....
This $1,137,301 federal Project Grant awarded by the Defense Health Agency on July 1, 2024 supports The Johns Hopkins University's work on "MULTI-MODAL, REMOTE TRACKING OF ALS PROGRESSION USING NOVEL DIGITAL BIOMARKERS" through June 30, 2026. The grant is funded under the Military Medical Research and Development program (CFDA 12.420), which supports biomedical research to improve the health and care of military service members, veterans, and their families. The project aims to develop...
The Department of the Army Medical Command awarded a $1,180,437 Project Grant to the University of California, Los Angeles (UCLA) under the Military Medical Research and Development program (CFDA 12.420). The grant supports UCLA's research to evaluate circulating cell-free DNA as a biomarker for diagnosing and tracking the progression of amyotrophic lateral sclerosis (ALS). The award began on March 1, 2024 and is scheduled for completion by February 28, 2026. Through this Project Grant, UCLA...
This federal Project Grant award of $704,431.23 from the Defense Health Agency (CFDA 12.420 - Military Medical Research and Development) to Meso Scale Diagnostics LLC, doing business as Meso Scale Discovery, supports the development of ultrasensitive plasma and cerebrospinal fluid immunoassays to enable clinical trials for amyotrophic lateral sclerosis (ALS). As a for-profit limited liability company specializing in assay development, laboratory testing, and related products for biomedical...
This Project Grant award of $2,163,115.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research conducted by Pathmaker Neurosystems Inc. to develop a noninvasive neuromodulation approach to slow the progression of amyotrophic lateral sclerosis (ALS) by suppressing neuronal hyperexcitability. The research, taking place in Boston, MA, aims to explore this innovative therapeutic method over the 2-year performance period...
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $798,272 project grant to The Johns Hopkins University on March 15, 2025. The grant will fund a 2-year research project titled "Testing the Use of WNT Inhibitors as a Therapeutic to Reverse TDP-43 Dysfunction in ALS." The research aims to develop novel therapeutic approaches for amyotrophic lateral sclerosis (ALS) by investigating the use of WNT inhibitors to address TDP-43 protein...
The University of Massachusetts Medical School was awarded a $836,992 Project Grant by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant, awarded on August 1, 2025, will fund research to investigate the effects of military-associated environmental toxins on motor neurons and glial cells in sporadic amyotrophic lateral sclerosis (ALS). The research aims to transform healthcare for military service members, veterans, and the broader...
This federal Project Grant award, valued at $1,103,084.00, was issued by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The funding supports the development of a personalized blood-based diagnostic assay for early detection of Amyotrophic Lateral Sclerosis (ALS) at Arizona State University. The university will collaborate with a sub-awardee, Georgetown University, to conduct the research. The project aims to transform healthcare for...
The Defense Health Agency awarded a $1.19 million Project Grant to The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. from May 1, 2023 to April 30, 2026 under the Military Medical Research and Development program (CFDA 12.420). The grant funds research into targeting excessive sphingolipid synthesis for treatment of amyotrophic lateral sclerosis (ALS) being conducted by Dr. Teresa M. Dunn of the Uniformed Services University of the Health Sciences. Dr. Dunn is...